Ravi Kaushik

Member of the Board of Directors at MassMEDIC

Speaker

With more than 25 years of global leadership experience across the United States, Asia-Pacific, and Europe, Ravi Kaushik is a transformative MedTech and biopharma executive uniquely positioned to serve as CEO of a medtech & drug-delivery medical device company. His career spans executive roles at top healthcare and life sciences organizations—including Takeda Pharmaceuticals, Transasia Biomedicals, Medtronic, Baxter/Baxalta, and GE Healthcare—where he has led innovation, scaled businesses, and delivered strong financial and operational performance.

At Takeda, as Vice President and Global Head of Device, Digital Innovation & Product Strategy, Ravi has led cross-functional device, digital health, and drug-delivery platform development, building an integrated ecosystem of connected therapeutics and advanced delivery technologies for patients and diagnostics, automation and robotics for plasma donors. He also stood up an internal medtech “startup” within a $7.5B business unit (Plasma Derived Therapies), demonstrating his ability to architect and scale transformative device strategies in complex global settings.

As CEO of Transasia Biomedicals, India’s largest IVD company, he successfully led a 1,000-employee organization with full P&L responsibility (~$120M), driving organizational strategy, commercial excellence, manufacturing, R&D, and global expansion. His proven ability to run an end-to-end healthcare technology enterprise underscores his readiness to lead a medical device company with both operational rigor and visionary direction.

Ravi’s Asia-Pacific leadership at Medtronic included steering a $120M diabetes therapy portfolio across Japan, Korea, ANZ, and Southeast Asia. He led multiple new product launches, advanced regional market development, built patient-centric business models, and achieved record-setting growth—earning multiple global CEO awards for transformative leadership and high-performance team engagement.

Earlier at Baxter/Baxalta, he led Strategy, Innovation, and P&L for India and APAC markets, where he delivered 40%+ revenue growth, championed business-model innovation for chronic care therapies, and developed new patient-access models that generated multimillion-dollar growth. His experience driving innovation at the intersection of therapeutics and delivery models directly strengthens his fit for modern drug-delivery enterprise leadership.